Home›Clinical trials›Virginia

GLP-1 clinical trials in Virginia: 25 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

25 GLP-1 clinical trials are recruiting at 40 sites in 13 cities across Virginia. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Virginia

  1. Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

    Phase 4. Run by University of Virginia. Registry number NCT03883412.

    A study testing whether a GLP-1 medicine, liraglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 21 to 60, have type 2 diabetes.

    1 site in Virginia

  2. Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

    Phase 4. Run by University of Virginia. Registry number NCT04575844.

    A study of a GLP-1 medicine, liraglutide, in people with metabolic syndrome.

    Who can join. Adults 21 to 60, have metabolic syndrome, BMI 25+.

    1 site in Virginia

  3. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in Virginia

    • Kidney and Hypertension Specialists, PLLC, Manassas. 703-361-7341

  4. Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

    Phase 4. Run by University of Virginia. Registry number NCT07178145.

    A study of a GLP-1 medicine, semaglutide, in people with heart failure with preserved ejection fraction.

    Who can join. Adults 18 to 90, have heart failure with preserved ejection fraction.

    1 site in Virginia

  5. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    4 sites in Virginia

    • Eximia Research - Norfolk, Norfolk
    • Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
    • Virginia Commonwealth University (VCU) Medical Center, Richmond. 804-828-4060
    • Gastroenterology Consultants of Southwest Virginia, Roanoke

  6. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    4 sites in Virginia

    • Stroobants Cardiovascular Center, Lynchburg
    • Carient Heart & Vascular - Manassas, Manassas. 703-335-8750
    • Clinical Research Partners, LLC, Richmond. 804-477-3045
    • Gershon Pain Specialists, Virginia Beach. 757-496-2050

  7. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    3 sites in Virginia

  8. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    3 sites in Virginia

    • Health Res of Hampton Roads, Newport News
    • Tidewater Physicians Multispecialty Group, Newport News
    • National Clin Res Inc., Richmond

  9. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    2 sites in Virginia

  10. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    2 sites in Virginia

  11. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    2 sites in Virginia

    • Health Research of Hampton Roads, Inc., Newport News. 757-591-8100
    • Urology of Virginia, Virginia Beach

  12. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Virginia

    • Kailera Clinical Site, Manassas
    • Kailera Clinical Site, Richmond

  13. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Virginia

    • Research Site, Leesburg
    • Research Site, Norfolk

  14. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Virginia

    • VCU Health - Center for Endocrinology Diabetes and Metabolism, Richmond

  15. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Virginia

    • Gastroenterology Consultants of Southwest Virginia, Roanoke

  16. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Run by Vanda Pharmaceuticals. Registry number NCT07446439.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    1 site in Virginia

  17. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Virginia

    • Tidewater Physicians Multispecialty Group, Newport News. 833-602-2368

  18. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07770841.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Virginia

    • Selma Medical Associates, Winchester

  19. Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

    Phase 2. Run by University of Virginia. Registry number NCT05424003.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with nafld reduce liver fat.

    Who can join. Adults 18 to 75, have nafld, BMI 27+.

    1 site in Virginia

    • Virginia Commonwealth University, Richmond

  20. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Virginia

    • Sovah Clinical Research-River District, Danville. 434-793-4711
The other 5 studies recruiting in Virginia

  1. Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy

    Phase 2. Run by University of Virginia. Registry number NCT06903923.

    A study of a GLP-1 medicine in young people with obesity.

    Who can join. Ages 12 to 21, have obesity.

    1 site in Virginia

    • University of Virginia Medical Center, Charlottesville. 434-243-6911

  2. Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

    Phase 2. Run by University of Colorado, Denver. Registry number NCT06975111.

    A study of a GLP-1 medicine, semaglutide, in women going through menopause.

    Who can join. Adults 45 to 55, women only, are going through menopause.

    1 site in Virginia

  3. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Run by Biomea Fusion Inc. Registry number NCT07502508.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    1 site in Virginia

    • Burke Internal Medicine and Research, Burke

  4. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Virginia

    • National Clin Res Inc., Richmond

  5. Strength Training Response of Muscle in GLP-1 Users

    Run by Virginia Polytechnic Institute and State University. Registry number NCT07104539.

    A study listed on ClinicalTrials.gov.

    1 site in Virginia

    • Virginia Tech, Blacksburg

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.